Pulmonary Hypertension Research

Author: Shelley Ensz. Scleroderma is highly variable. See Types of Scleroderma. Read Disclaimer
Causes of PH
Ineffective Therapies


Active research for pulmonary hypertension is largely focusing on causes, antibodies, and treatments. (Also see Pulmonary Hypertension Overview, Scleroderma Lung Involvement, What is Scleroderma?, Types of Scleroderma, and Systemic Sclerosis)

Recent advances in scleroderma-associated (SSc) - pulmonary hypertension. Although there have been many recent advances in SSc-pulmonary hypertension, further research is needed in order to prevent/cure this deadly complication. PubMed, Curr Opin Rheumatol, 2014 Nov;26(6):637-45.


Interferon and alternative activation of macrophage/monocytes in systemic sclerosis-associated pulmonary arterial hypertension. This study explores the relationship between biomarkers of pulmonary arterial hypertension (PAH), interferon-regulated gene expression and alternatively activated macrophages (AAM) in systemic sclerosis (SSc). Romy B. Christmann MD, PhD, Arthritis and Rheumatism.


What Causes Pulmonary Hypertension? Certain factors appear to increase your chances of developing pulmonary arterial hypertension (PAH). National Heart, Blood and Lung Institute.

T-Helper 17 Cell Polarization in Pulmonary Arterial Hypertension. T helper 17 cell immune polarization in patients with PAH has been highlighted, as has been previously demonstrated in other chronic inflammatory and autoimmune conditions. Chest, 2015;147(6):1610-1620.

Ineffective Therapies

Calcium channel blockers do not protect scleroderma patients from developing pulmonary hypertension

Immunosuppressives do not prevent pulmonary hypertension in scleroderma patients.

Prevalence of PH/PAH in Scleroderma (Systemic Sclerosis, SSc)

Prevalence of pulmonary arterial hypertension (PAH) in patients with connective tissue diseases: a systematic review of the literature. Prevalence of PAH in patients with connective tissue diseases was substantially higher than that of idiopathic PAH based on pooled prevalence estimates. PubMed, Clin Rheumatol. (Also see Connective Tissue Disease)

"PAH in SSc occurs in a significant proportion of (systemic scleroderma) patients without any "red flag signs" in early stages." Journal of Association of Physicians of India.

Go to Secondary Pulmonary Hypertension
Recent Donors
See ISN News for recent donors, including memorials for
Christine Kane, Joleen M. Cascaden.

SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA

Email [email protected] to request our Welcome email, or to report bad links or to update this page content.

TOLL FREE HOTLINE 800-564-7099
Free to U.S. and Canadian Callers. Ask for our Free Info Packet by mail or email!
Scleroderma, Pulmonary Arterial Hypertension, and related illnesses.
Privacy Policy.

The most important thing in the world to know about scleroderma is!
Donate Now
Copyright 1998-2017, International Scleroderma Network. AKA Scleroderma from A to Z and SCLERO.ORG. All Rights Reserved.